SummarySHR-1701, a bispecific fusion protein directed against PD-L1 and TGFβ, demonstrates promising clinical activity in advanced/recurrent cervical cancer. A recent study serves as a proof of principle that the TGFβ pathway may be successfully targeted, and that bispecific antibodies offer a novel therapeutic approach to do so.See related article by Feng et al., p. 5297

中文翻译：

---

双功能阻断：宫颈癌的新型免疫治疗方法

摘要SHR-1701 是一种针对 PD-L1 和 TGFβ 的双特异性融合蛋白，在晚期/复发性宫颈癌中表现出有希望的临床活性。最近的一项研究证明了 TGFβ 通路可能被成功靶向，并且双特异性抗体为此提供了一种新的治疗方法。参见 Feng 等人的相关文章，第 17 页。5297